Anterogen saw the highest growth of 0.99% in patent filings in June and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Anterogen’s patent filings and grants. Buy the databook here.
Anterogen has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 50% of filings. The Australia(AU), Israel(IL), and United States(US) patent Office are among the top ten patent offices where Anterogen is filings its patents. Among the top granted patent authorities, Anterogen has 100% of its grants in United States(US).
Mesoblast could be the strongest competitor for Anterogen
Viral infections related patents lead Anterogen portfolio followed by varicella zoster (hhv-3) infections, and postherpetic neuralgia
Anterogen has highest number of patents in viral infections followed by varicella zoster (hhv-3) infections, postherpetic neuralgia, chicken pox, and herpes zoster (shingles). For viral infections, nearly 50% of patents were filed and 20% of patents were granted in Q2 2024.
For comprehensive analysis of Anterogen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.